BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 20226097)

  • 1. HEPACAM1 and 2 are differentially regulated in canine mammary adenomas and carcinomas and its lymph node metastases.
    Klopfleisch R; Klose P; da Costa A; Brunnberg L; Gruber AD
    BMC Vet Res; 2010 Mar; 6():15. PubMed ID: 20226097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RAD51 protein expression is increased in canine mammary carcinomas.
    Klopfleisch R; Schütze M; Gruber AD
    Vet Pathol; 2010 Jan; 47(1):98-101. PubMed ID: 20080488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin receptor is expressed in normal canine mammary gland and benign adenomas but decreased in metastatic canine mammary carcinomas similar to human breast cancer.
    Klopfleisch R; Hvid H; Klose P; da Costa A; Gruber AD
    Vet Comp Oncol; 2010 Dec; 8(4):293-301. PubMed ID: 21062411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of p27 expression in canine mammary tumors and their metastases.
    Klopfleisch R; Schütze M; Gruber AD
    Res Vet Sci; 2010 Apr; 88(2):300-3. PubMed ID: 19748645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of cell cycle regulators p21, p27 and p53 in metastasizing canine mammary adenocarcinomas versus normal mammary glands.
    Klopfleisch R; Gruber AD
    Res Vet Sci; 2009 Aug; 87(1):91-6. PubMed ID: 19185891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sialyl Lewis x expression in canine malignant mammary tumours: correlation with clinicopathological features and E-Cadherin expression.
    Pinho SS; Matos AJ; Lopes C; Marcos NT; Carvalheira J; Reis CA; Gärtner F
    BMC Cancer; 2007 Jul; 7():124. PubMed ID: 17617904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased expression of BRCA2 and RAD51 in lymph node metastases of canine mammary adenocarcinomas.
    Klopfleisch R; Gruber AD
    Vet Pathol; 2009 May; 46(3):416-22. PubMed ID: 19176491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a malignant progression associated with a linear change in protein expression levels from normal canine mammary gland to metastatic mammary tumors?
    Klose P; Weise C; Bondzio A; Multhaup G; Einspanier R; Gruber AD; Klopfleisch R
    J Proteome Res; 2011 Oct; 10(10):4405-15. PubMed ID: 21888431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Derlin-1 and stanniocalcin-1 are differentially regulated in metastasizing canine mammary adenocarcinomas.
    Klopfleisch R; Gruber AD
    J Comp Pathol; 2009; 141(2-3):113-20. PubMed ID: 19515379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and significance of PTEN in canine mammary gland tumours.
    Qiu C; Lin D; Wang J; Wang L
    Res Vet Sci; 2008 Oct; 85(2):383-8. PubMed ID: 18082231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of transforming growth factor β (TGFβ) and latent TGFβ binding protein (LTBP)-4 expression in late stage canine mammary tumours.
    Klopfleisch R; Schütze M; Gruber AD
    Vet J; 2010 Dec; 186(3):379-84. PubMed ID: 19836277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of CD44 in canine mammary tumours.
    Paltian V; Alldinger S; Baumgärtner W; Wohlsein P
    J Comp Pathol; 2009 Nov; 141(4):237-47. PubMed ID: 19592009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased Derlin-1 expression in metastases of canine mammary adenocarcinomas.
    Klopfleisch R; Schütze M; Linzmann H; Brunnberg L; Gruber AD
    J Comp Pathol; 2010 Jan; 142(1):79-83. PubMed ID: 19632687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of TopBP1 in canine mammary neoplasia in relation to histological type, Ki67, ERalpha and p53.
    Morris JS; Nixon C; King OJ; Morgan IM; Philbey AW
    Vet J; 2009 Mar; 179(3):422-9. PubMed ID: 18314357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER-2 expression in canine morphologically normal, hyperplastic and neoplastic mammary tissues and its correlation with the clinical outcome.
    Ressel L; Puleio R; Loria GR; Vannozzi I; Millanta F; Caracappa S; Poli A
    Res Vet Sci; 2013 Apr; 94(2):299-305. PubMed ID: 23141215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MUC1 expression in canine malignant mammary tumours and relationship to clinicopathological features.
    de Oliveira JT; Pinho SS; de Matos AJ; Hespanhol V; Reis CA; Gärtner F
    Vet J; 2009 Dec; 182(3):491-3. PubMed ID: 18948041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of VEGF-C expression in canine mammary tumours.
    Qiu C; Lin DD; Wang HH; Qiao CH; Wang J; Zhang T
    Aust Vet J; 2008 Jul; 86(7):279-82. PubMed ID: 18616481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical expression of caveolin-1 in normal and neoplastic canine mammary tissue.
    Amorim I; Lopes CC; Faustino AM; Pereira PD
    J Comp Pathol; 2010 Jul; 143(1):39-44. PubMed ID: 20153867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
    Hanrahan V; Currie MJ; Gunningham SP; Morrin HR; Scott PA; Robinson BA; Fox SB
    J Pathol; 2003 Jun; 200(2):183-94. PubMed ID: 12754739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of Mammalian target of rapamycin in canine mammary carcinomas: an immunohistochemical study.
    Delgado L; Gärtner F; Dias Pereira P
    J Comp Pathol; 2015; 152(2-3):138-44. PubMed ID: 25670666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.